Current use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for hypertension in patients with chronic kidney disease with proteinuria: a cross-sectional study based on real-world data
Authors:
- 19 September 2024
- journal article
- research article
- Published by Springer Nature in Hypertension Research
- Vol. 48 (1) , 244-255
Abstract
Japanese guidelines recommend angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) as first-line therapy in hypertensive patients with chronic kidney disease (CKD) and proteinuria, but calcium channel blockers in patients with stage G4–5 CKD aged ≥75 years; however, the implementation of these guidelines in clinical practice is unclear. We investigated the actual use of these agents in this patient population. We conducted a cross-sectional study using the DeSC database, which includes anonymous information from various health insurance systems in Japan. A total of 34,362 hypertensive patients aged p < 0.001). Patients with CKD stage G1 had the lowest prescription rates for ARBs/ACEIs in both age categories. These results indicate that, despite guideline recommendations, ARBs/ACEIs are insufficiently prescribed for patients with hypertension associated with CKD with proteinuria. ARBs and ACEIs were only used in 28% of hypertensive patients aged<75 years (CKD stage G1–G5) or aged ⩾75 years (CKD stage G1–G3), with urinary protein ⩾1+, for whom Japanese guidelines recommend ARBs/ACEIs. The prescription rate was lower in the younger compared with the older patients.Keywords
This publication has 16 references indexed in Scilit:
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)Hypertension Research, 2019
- Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trialsHypertension Research, 2019
- Analysis of antihypertensive treatment using real-world Japanese data—the retrospective study of antihypertensives for lowering blood pressure (REAL) studyHypertension Research, 2019
- Current prescription status of antihypertensive drugs in Japanese patients with hypertension: Analysis by type of comorbiditiesClinical and Experimental Hypertension, 2018
- Lifetime Risk of Stage 3–5 CKD in a Community-Based Sample in IcelandClinical Journal of the American Society of Nephrology, 2015
- Blood Pressure, Proteinuria, and Renal Function Decline: Associations in a Large Community-Based PopulationAmerican Journal of Hypertension, 2015
- Elevated systolic blood pressure is associated with increased incidence of chronic kidney disease but not mortality in elderly veteransJournal of the American Society of Hypertension, 2015
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference reportKidney International, 2011
- Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J StudyHypertension Research, 2009
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001